We are proud to announce that three members of our team have been recognized by Managing IP. Dr. Jacqueline Lui and Ms. Pauli Wong have been recognized as a Patent Star and Mr. Eddie Ho as a Rising Star by ManagingIP. These prestigious awards acknowledge their exceptional expertise and invaluable contributions to the field of intellectual property.

Dr. Lui is widely recognized as a leading expert in patent law, specializing in cross-jurisdiction patent prosecution and strategy. With over 20 years of experience in IP, she has provided invaluable guidance to startups, Fortune 500 companies, and HK/Nasdaq-listed companies. Her expertise encompasses various critical areas, including IP strategy, portfolio management, technology transfer, due diligence, and enforcement. Dr. Lui's exceptional track record and unwavering commitment to excellence have solidified her reputation as a trusted advisor in the field.

Ms. Pauli Wong oversees the patent drafting team at Eagle IP and assists local and international clients with patent prosecution across a wide range of technology fields. She helps clients navigate IP rights, portfolio management, and global filing strategy for innovations in areas like biotechnology, medical devices, and robotics. Pauli is passionate about empowering Hong Kong innovators, leveraging her ability to quickly understand new technologies, meticulous prosecution skills, strategic business acumen, and commitment to client service.

Mr. Eddie Ho is a qualified Chinese Patent Attorney and has quickly amassed extensive experience drafting and prosecuting patent applications in a broad range of areas, including biology, biotechnology, medical devices, diagnostics, material science, engineering, and software. He helps inventors and companies manage and navigate complex patent portfolios and is exceptionally strong at inter-disciplinary technologies.

Let us come together to celebrate this well-deserved accolade for Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho and to recognize their exceptional dedication to the dynamic world of intellectual property.

我們過去活動

Recommended Insights

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

How a Secondhand Ground Brush Wiped Away a Chinese Patent

2024年12月4日
A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor.  Highlights Background  With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no […]
Top crossarrow-right